HD-MB03 Xenograft Model Service for Medulloblastoma

The HD-MB03 xenograft model represents one of the most clinically relevant preclinical platforms for Group 3 medulloblastoma, a high-risk pediatric brain tumor subtype characterized by MYC amplification and metastatic potential. Alfa Cytology leverages this established cell line to deliver robust, reproducible xenograft services that accelerate your drug discovery and translational research programs from lead optimization to IND-enabling studies.

Overview of HD-MB03 Xenograft Model for Medulloblastoma

Medulloblastoma is the most common malignant brain tumor in childhood and is now recognized as comprising at least four molecular subgroups---WNT, SHH, Group 3, and Group 4---each with distinct biology, clinical presentation, and outcome. Group 3 medulloblastoma carries the poorest prognosis, frequently presenting with metastatic disease at diagnosis and harboring hallmark genomic alterations including MYC amplification and isochromosome 17q [i(17q)]. The HD-MB03 cell line was established in 2011 from tumor material of a 3-year-old male patient with metastasized Group 3 medulloblastoma, and it has since become a cornerstone model for preclinical evaluation of epigenetic therapies, radiation sensitizers, and MYC-targeted agents.

HD-MB03 cells exhibit large-cell anaplastic morphology in vitro, maintain long-term proliferative capacity in adherent monolayer culture, and faithfully recapitulate the molecular signature of the original tumor upon orthotopic transplantation. The cell line retains key Group 3 markers including high Ki67 proliferation index, wild-type TP53, and GFAP expression, alongside characteristic cytogenetic abnormalities. In vivo, HD-MB03 forms aggressive, metastatic tumors that disseminate along the leptomeninges and spinal canal, mirroring the clinical behavior of high-risk human disease and providing a stringent testbed for therapeutic efficacy against both primary and disseminated disease.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting Group 3 medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression and leptomeningeal dissemination, and how treatments intersect with MYC-driven oncogenic signaling.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for HDAC inhibitor sensitivity.

Figure 1. Integrin-alphavbeta3 is differentially expressed in medulloblastoma cell lines and promotes their proliferation, migration, and invasion. (Echavidre, William, et al., 2023)

Cell Line Information: HD-MB03

The HD-MB03 cell line is a well-characterized, authenticated human medulloblastoma model deposited with the DSMZ (ACC-740) and registered under RRID:CVCL_S506. Its classification within Group 3 medulloblastoma and retention of metastatic potential in vivo makes it unique among available medulloblastoma cell lines and essential for preclinical research targeting the most aggressive pediatric brain tumor subtype.

Our Services

At Alfa Cytology, we specialize in delivering validated, high-fidelity HD-MB03 xenograft models tailored to your preclinical research objectives. Our integrated service platform spans from cell line authentication and orthotopic implantation to longitudinal tumor monitoring, biomarker analysis, and comprehensive histopathological endpoints---ensuring that every study generates publication-quality data to support your IND-enabling and mechanistic discovery programs.

Workflow of HD-MB03 Xenograft Model Construction

The construction of a robust HD-MB03 xenograft model requires meticulous attention to cell preparation, surgical technique, and post-operative monitoring. Our standardized workflow ensures reproducible tumor take rates and physiologically relevant disease progression suitable for pharmacological and mechanistic studies. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation and Quality Control: HD-MB03 cells are expanded from authenticated, low-passage stocks (<=P10) under standard culture conditions. Prior to implantation, cells undergo mycoplasma PCR screening, viability assessment by trypan blue exclusion (>95% viability required), and STR authentication confirmation.
2. Orthotopic Injection: Anesthetized immunodeficient mice (typically NOD-scid or NSG) receive stereotactic injection of 1--5 x 10^5 HD-MB03 cells resuspended in serum-free medium with Matrigel (1:1) into the cerebellar vermis or fourth ventricle, ensuring anatomical fidelity to the tumor's natural site of origin.
3. Post-Operative Monitoring: Mice are recovered on a warming pad with continuous respiratory and reflex monitoring. Analgesia is administered per IACUC guidelines, and animals are housed in pathogen-free barrier facilities with daily health checks for the first 72 hours.
4. Tumor Establishment and Longitudinal Assessment: Tumor growth is monitored via bioluminescence imaging (BLI) for luciferase-expressing derivatives, or by MRI for non-labeled lines, beginning at Day 7 post-implantation and continuing at defined intervals to track primary tumor burden and metastatic dissemination.
5. Endpoint Analysis and Sample Collection: At study termination, mice are perfused with PBS followed by 4% paraformaldehyde. Brains and spinal cords are harvested for histopathology (H&E, IHC for Ki67, GFAP, cleaved caspase-3), molecular profiling (qPCR, Western blot), and metastasis mapping via serial sectioning of the neuraxis.

Figure 2: Schematic workflow illustrating the derivation and construction of the HD-MB03 Xenograft Model at Alfa Cytology.

Case Study-HD-MB03 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established orthotopic HD-MB03 xenografts in NSG mice to evaluate a novel MYC-pathway inhibitor candidate. Tumors engrafted with 100% take rate within 14--21 days, displaying characteristic large-cell anaplastic histology and robust Ki67 staining. Longitudinal BLI revealed progressive tumor growth with detectable leptomeningeal dissemination by Day 28. Treatment cohorts demonstrated dose-dependent tumor growth inhibition and extended median survival compared to vehicle controls. Detailed quantitative data, including tumor volume kinetics, survival curves, and biomarker modulation, are available upon request under confidentiality agreement.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HD-MB03 xenograft program means accessing a fully integrated preclinical CRO with deep expertise in pediatric brain tumor models, rigorous quality standards, and flexible study designs that align with your regulatory and publication goals.

• Verified Cell Line Integrity: Authenticated, low-passage HD-MB03 cell stocks with verified STR profiles and routine mycoplasma screening ensure genetic fidelity across every study.
• High Take Rates and Consistency: Standardized orthotopic surgical protocols in immunodeficient strains deliver reproducible tumor take rates (>95%) and physiologically relevant metastatic dissemination patterns.
• Integrated Imaging Capabilities: Multimodal tumor monitoring via BLI, MRI, and histopathology provides comprehensive pharmacodynamic and efficacy readouts from a single model system.
• Tailored Study Designs: Customizable treatment arms---including single-agent, combination, and radiation-sensitization studies---are designed to meet your specific mechanistic or IND-enabling objectives.
• Standardized Protocols: All studies are conducted under IACUC-approved protocols with GLP-compliant documentation, ensuring data integrity and regulatory readiness.

Contact Us

Ready to advance your medulloblastoma therapeutic pipeline with a validated HD-MB03 xenograft model? Reach out to Alfa Cytology today to discuss your study design, receive a customized proposal, and leverage our preclinical expertise to de-risk your drug development journey. Please reach out to us today via our inquiry form or email to learn more about our HD-MB03 Xenograft Model services.

For research use only. Not intended for any clinical use.